CAR-T cells against the CD19 protein have been shown to be effective against acute lymphoblastic leukemia, B cell lymphoma and lymphocytic leukemia, and have been approved by the FDA and EMA in those settings. Here, CD19 is linked to acute lymphoblastic leukemia.